The estimated Net Worth of David Piacquad is at least $15.2 Million dollars as of 6 February 2020. Mr. Piacquad owns over 9,264 units of AMGEN stock worth over $13,100,206 and over the last 11 years he sold AMGN stock worth over $2,130,072. In addition, he makes $0 as Senior Vice President - Business Development at AMGEN.
David has made over 5 trades of the AMGEN stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 9,264 units of AMGN stock worth $2,130,072 on 6 February 2020.
The largest trade he's ever made was exercising 15,000 units of AMGEN stock on 11 May 2018 worth over $820,650. On average, David trades about 938 units every 15 days since 2014. As of 6 February 2020 he still owns at least 39,700 units of AMGEN stock.
You can see the complete history of Mr. Piacquad stock trades at the bottom of the page.
David A. Piacquad serves as Senior Vice President - Business Development of the Company. Mr. Piacquad joined the Company in 2010 and served as Vice President, Strategy and Corporate Development until his appointment to the role of Vice President, Business Development in 2014. Prior to joining the Company, from 2009 to 2010, Mr. Piacquad was Principal of David A. Piacquad Consulting LLC. From 2006 to 2009, Mr. Piacquad served as Senior Vice President, Business Development and Licensing, for Schering-Plough Corporation (Schering-Plough). Prior to Schering-Plough, Mr. Piacquad served in a series of leadership roles in finance and business development at J&J, with his last position being Vice President, Ventures and Business Development.
David Piacquad is 63, he's been the Senior Vice President - Business Development of AMGEN since 2014. There are 6 older and 19 younger executives at AMGEN. The oldest executive at AMGEN Inc. is Fred Hassan, 74, who is the Independent Director.
David's mailing address filed with the SEC is ONE AMGEN CENTER DRIVE, , THOUSAND OAKS, CA, 91320-1799.
Over the last 22 years, insiders at AMGEN have traded over $219,663,137 worth of AMGEN stock and bought 8,904 units worth $919,219 . The most active insiders traders include Robert Eckert, Kevin W Sharer und Ellen Jamison Kullman. On average, AMGEN executives and independent directors trade stock every 35 days with the average trade being worth of $8,732,261. The most recent stock trade was executed by Nancy A. Grygiel on 3 May 2024, trading 2,117 units of AMGN stock currently worth $662,812.
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
AMGEN executives and other stock owners filed with the SEC include: